Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 17,295 Shares

Key Points

• Richard Daniell, EVP of Teva, sold 17,295 shares on March 5 at an average price of $31.67 for $547,732.65, reducing his holding by 16.78% to 85,755 shares (≈$2.72M).
• Teva beat Q4 expectations (EPS $0.96 vs $0.65 est, revenue $4.71B), set FY2026 guidance of 2.570–2.770 EPS, and saw multiple analyst price-target upgrades with an average target around $37.67.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Richard Daniell sold 17,295 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares in the company, valued at approximately $2,715,860.85. The trade was a 16.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Richard Daniell also recently made the following trade(s):

• On Tuesday, December 9th, Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.39 during trading on Monday, hitting $31.44. The company's stock had a trading volume of 11,093,245 shares, compared to its average volume of 9,695,220. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The business's 50 day simple moving average is $33.01 and its 200-day simple moving average is $26.32. The firm has a market cap of $36.15 billion, a PE ratio of 26.20, a P/E/G ratio of 10.39 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TEVA shares. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. Bank of America raised their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, December 9th. Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, January 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 31st. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $37.67.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC boosted its stake in Teva Pharmaceutical Industries by 28.4% during the fourth quarter. Corient Private Wealth LLC now owns 49,063 shares of the company's stock valued at $1,531,000 after buying an additional 10,843 shares during the last quarter. Dorsey Wright & Associates bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $1,640,000. Compound Planning Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $323,000. Invesco Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 4.8% during the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company's stock worth $84,582,000 after acquiring an additional 124,304 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $463,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.